tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Cadrenal announces acquisition of assets of eXIthera Pharmaceuticals
PremiumThe FlyCadrenal announces acquisition of assets of eXIthera Pharmaceuticals
3M ago
Cadrenal Therapeutics Advances Tecarfarin Development
Premium
Company Announcements
Cadrenal Therapeutics Advances Tecarfarin Development
4M ago
Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)
Premium
The Fly
Cadrenal Therapeutics reports Q2 EPS ($1.87), consensus ($1.77)
4M ago
Cadrenal Therapeutics Reports Increased Losses Amid R&D Expansion
PremiumCompany AnnouncementsCadrenal Therapeutics Reports Increased Losses Amid R&D Expansion
7M ago
Cadrenal Therapeutics Advances Tecarfarin Development in 2024
Premium
Company Announcements
Cadrenal Therapeutics Advances Tecarfarin Development in 2024
9M ago
Cadrenal Therapeutics  teams with Abbott inTECH-LVAD trial
Premium
The Fly
Cadrenal Therapeutics teams with Abbott inTECH-LVAD trial
9M ago
Cadrenal Therapeutics target adjusted to $32 from $3 at H.C. Wainwright
PremiumThe FlyCadrenal Therapeutics target adjusted to $32 from $3 at H.C. Wainwright
1y ago
Cadrenal Therapeutics Advances Tecarfarin Development
Premium
Company Announcements
Cadrenal Therapeutics Advances Tecarfarin Development
1y ago
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin
Premium
Company Announcements
Cadrenal Therapeutics Raises $5.1 Million for Tecarfarin
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100